Neuroendocrine Cancer Treatments and Advances in Radioligand Therapy

As part of the Neuroendocrine Cancer UK Virtual Summit 2020, Dr Amy Eccles speaks about the spectrum of treatments for Neuroendocrine Cancer as well as advances & options in Radioligland Therapy.

[@DCGreenZone]

>>Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity’s 67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical response to treatment and an indicator of the recurrence of disease for prostate cancer.